<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869817</url>
  </required_header>
  <id_info>
    <org_study_id>IA0147</org_study_id>
    <secondary_id>U19AG032438</secondary_id>
    <nct_id>NCT00869817</nct_id>
  </id_info>
  <brief_title>Dominantly Inherited Alzheimer Network (DIAN)</brief_title>
  <acronym>DIAN</acronym>
  <official_title>Dominantly Inherited Alzheimer Network (DIAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify potential biomarkers that may predict the
      development of Alzheimer's disease in people who carry an Alzheimer's mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and
      is an important model for study because the responsible mutations have known biochemical
      consequences that are believed to underlie the pathological basis of the disorder. Three
      major hypotheses will be tested:

        -  First, that there is a period of preclinical (presymptomatic) AD in individuals who are
           destined to develop early-onset dementia (gene carriers) that can be detected by changes
           in biological fluids and in neuroimaging correlates in comparison with individuals who
           will not develop early-onset dementia (non-carriers).

        -  Second, because all identified causative mutations for AD affect the normal processing
           of amyloid precursor protein (APP) and increase brain levels of amyloid-beta 42 (Aβ42),
           the sequence of preclinical changes initially will involve Aβ42 (production and
           clearance; reduced levels in cerebrospinal fluid [CSF]), followed by evidence for
           cerebral deposition of Aβ42 (amyloid imaging), followed by cerebral metabolic activity
           (functional imaging), and finally by regional atrophy (structural imaging).

        -  Finally, that the phenotype of symptomatic early-onset familial AD, including its
           clinical course, is similar to that of late-onset &quot;sporadic&quot; AD.

      The following specific aims will be used to test these hypotheses:

        1. Maintain the established international DIAN registry of individuals (mutation carriers
           and non-carriers; pre-symptomatic and symptomatic) who are biological adult children of
           a parent with a known causative mutation for AD in the APP, PSEN1, or PSEN2 genes and
           assess participants every 2 years with the uniform DIAN protocol.

        2. Maintain the integrated DIAN database and biospecimen repository to disseminate data and
           tissue to qualified investigators (within and outside of DIAN) in a user-friendly manner
           and to permit analyses within, between, and among the various data domains that will
           include:

             1. In asymptomatic mutation carriers (using non-carriers as controls), determine the
                temporal ordering and rate of intraindividual change in clinical, cognitive,
                behavioral, imaging, and fluid biomarkers of AD prior to estimated age of symptom
                onset.

             2. In symptomatic mutation carriers, compare the clinical and neuropathological
                phenotypes of ADAD to those of LOAD, using datasets such as ADNI.

        3. Utilize the DIAN cohort and its database and biospecimen repository to support new
           scientific studies, including use of exome chip technology to examine potential
           modifiers of age at symptomatic onset, exploratory investigation of new biomarker
           analytes, imaging modalities and techniques, perform exploratory genetic analysis to
           test whether novel AD genes identified through GWAS and sequencing of late onset AD
           cases also influence variation in age at onset of changes in biomarker endophenotypes in
           FAD kindred, and generate genome-wide DNA methylation data for pilot study and perform
           exploratory analyses to look for changes in DNA methylation in longitudinal samples from
           DIAN participants.

        4. Provide genetic counseling to any and all DIAN participants who wish to learn their
           mutation status and, for those who decide to learn their status after counseling,
           provide genetic testing by Clinical Laboratory Improvement Amendments (CLIA) - approved
           laboratories (i.e., outside of DIAN).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive power of a biomarker or group of biomarkers</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical markers also examined from clinical interview and cognitive testing</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Mutation Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Mutation Negative</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      buffy coat, plasma, cerebral spinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mutation carriers and non-carriers from families with a mutation (which is different from
        the genetic risk factor Apo-E4) known to cause Alzheimer's disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from participant and collateral source prior to any
             study-related procedures.

          -  Aged 18 (inclusive) or older and the child of an affected individual (clinically or by
             testing) in a pedigree with a known mutation for ADAD.

          -  Cognitively normal. Primary enrollment will focus on recruitment of asymptomatic adult
             children who are more than 15 years younger than the estimated age of symptom onset.
             Enrollment of new participants with very mild, mild, or moderate cognitive impairment
             is allowed with the prior approval of the DIAN Coordinating Center.

          -  Has two persons who are not their full-blooded siblings who can serve as collateral
             sources for the study.

          -  Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade
             level (international equivalent) or above.

        Exclusion Criteria:

          -  Under age 18

          -  Medical or psychiatric illness that would interfere in completing initial and
             follow-up visits

          -  Requires nursing home level care

          -  Has no one who can serve as a study informant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J. Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DIAN Global Coordinator</last_name>
    <phone>314-747-1940</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Swisher, MS</last_name>
    <phone>314-747-1940</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-0080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Montoya</last_name>
      <phone>323-442-2357</phone>
      <email>Lucy.Montoya@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Helena Chui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Ringman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sochenda Chea, BHA CRC</last_name>
      <phone>904-953-3234</phone>
      <email>chea.sochenda@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neil R. Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University-Indiana Alzheimer Disease Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Buck, RN</last_name>
      <phone>317-963-1847</phone>
      <email>jilmbuck@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Bernardino Ghetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige Sparks, BA</last_name>
      <phone>617-643-7799</phone>
      <email>kpsparks@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jasmeer Chhatwal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sigurdson, RN, MPH</last_name>
      <phone>314-362-2256</phone>
      <email>sigurdsonw@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Donahue, RN, MS</last_name>
      <phone>314-362-2147</phone>
      <email>donahuet@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randall Bateman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Neimeyer</last_name>
      <phone>212-305-5909</phone>
      <email>Kn2416@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>James Noble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zana Ikonomovic, MD</last_name>
      <phone>412-692-2740</phone>
      <email>ikonomovics@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Berman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Bodge, PhD</last_name>
      <phone>401-455-6403</phone>
      <email>cbodge@butler.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Salloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia&quot; (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricio Chrem, MD</last_name>
      <phone>20565342</phone>
      <email>pchremmendez@fleni.org.ar</email>
    </contact>
    <investigator>
      <last_name>Ricardo Allegri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William S. Brooks, MBBS, MPH</last_name>
      <phone>+612 9399 1101</phone>
      <email>w.brooks@NeuRA.edu.au</email>
    </contact>
    <investigator>
      <last_name>Peter Schofield, PhD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Institute, University of Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3130</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Vidaurre, RN</last_name>
      <phone>+61 3 8344 1859</phone>
      <email>lesley.vidaurre@florey.edu.au</email>
    </contact>
    <investigator>
      <last_name>Colin Masters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Taddei</last_name>
      <phone>+61-(0)8-6304-5107</phone>
      <email>k.taddei@ecu.edu.au</email>
    </contact>
    <investigator>
      <last_name>Ralph Martins, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siri Houeland di Bari</last_name>
      <phone>+49 89 4400 46458</phone>
      <email>Siri.HouelandDiBari@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Levin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Kuder-Buletta</last_name>
      <phone>+49-(0)7071-2987584</phone>
      <email>Elke.Buletta@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Jucker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka City</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisako Fujii, PhD</last_name>
      <phone>+81-6-6645-3443</phone>
      <email>hfujii@med.osaka-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroyuki Shimada, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Queen Square</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Douglas, RN MPhil.</last_name>
      <phone>0044 (0)845 155 5000</phone>
      <phone_ext>723560</phone_ext>
      <email>jdouglas@drc.ion.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Martin Rossor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://dian.wustl.edu/</url>
    <description>DIAN Website</description>
  </link>
  <link>
    <url>http://knightadrc.wustl.edu/</url>
    <description>Washington University St. Louis Knight Alzheimer's Disease Research Center</description>
  </link>
  <reference>
    <citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446-52.</citation>
    <PMID>16894106</PMID>
  </reference>
  <reference>
    <citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.</citation>
    <PMID>17210801</PMID>
  </reference>
  <reference>
    <citation>Godbolt AK, Cipolotti L, Anderson VM, Archer H, Janssen JC, Price S, Rossor MN, Fox NC. A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase. 2005 Feb;11(1):56-64.</citation>
    <PMID>15804925</PMID>
  </reference>
  <reference>
    <citation>Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991 Apr;41(4):469-78.</citation>
    <PMID>2011242</PMID>
  </reference>
  <reference>
    <citation>Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005 May;62(5):758-65.</citation>
    <PMID>15883263</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>antecedent biomarkers</keyword>
  <keyword>Amyloid Precursor Protein (APP) mutation</keyword>
  <keyword>presenilin I (PS1) mutation</keyword>
  <keyword>presenilin 2 (PS2) mutation</keyword>
  <keyword>Autosomal Dominant Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

